In contrast, reduction or lack of CCND2 expression has also been reported in gastric cancer [20], breast cancer [37, 38], prostate cancer [39], and lung cancer [18], suggesting that CCND2 may function as a TSG. Here, CCND2 is linked to breast carcinoma.